Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Glycopyrrolate/indacaterol/mometasone - Novartis

Drug Profile

Glycopyrrolate/indacaterol/mometasone - Novartis

Alternative Names: Enerzair; Enerzair Breezhaler; ICS/LABA/LAMA inhaled triple therapy - Novartis; IND/GLY/MF; Indacaterol acetate, glycopyrronium bromide and mometasone furoate - Novartis; QVM 149

Latest Information Update: 20 Dec 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sosei Heptares; Vectura
  • Developer Novartis
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Bronchodilators; Corticosteroids; Glucocorticoids; Indans; Pregnadienediols; Pyrrolidines; Quaternary ammonium compounds; Quinolones; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Asthma

Most Recent Events

  • 16 Dec 2021 Novartis Pharmaceuticals withdraws the phase III XPERTT trial in Asthma in Canada (NCT04206761)
  • 05 Sep 2021 Pooled efficacy data from phase III PALLADIUM, IRIDIUM and ARGON trials in Asthma presented at 31st Annual Congress of the European Respiratory Society (ERS-2021)
  • 05 Sep 2021 Interim efficacy results from the phase III IRIDIUM trial in Asthma presented at 31st Annual Congress of the European Respiratory Society (ERS-2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top